Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06338670
Other study ID # CLTD5839
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date December 2024

Study information

Verified date May 2024
Source Cochlear
Contact Therese Agat
Phone +46766498562
Email tagat@cochlear.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant. Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 12
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Implanted with a Cochlear Osia Implant (OSI100 or OSI200) - Conductive or mixed hearing loss in the implanted ear. Bone conduction threshold 4-frequency pure tone average (PTA4; mean of bone conduction thresholds at 0.5, 1, 2 and 4 kHz) = 55 dB HL. OR Single-Sided Deafness in the implanted ear. Air Conduction threshold 4-frequency pure tone average (PTA4; mean of air conduction thresholds at 0.5, 1, 2 and 3 kHz) = 20 dB HL in the good ear. - Aged 18 years or older, at time of consent. - Minimum experience of 1 month with the Osia 2 Sound Processor. - Fluent speaker in the language used to assess speech perception performance. - Willing and able to provide written informed consent. Exclusion Criteria: - Sensitivity to loud sounds. - Ongoing infection at or around the sound processor area. - Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator. - Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator - Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling. - Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation. - Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cochlear Osia 3 Sound Processor
Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
Cochlearâ„¢ Osia® 2 Sound Processor
Osia® 2 Sound Processor

Locations

Country Name City State
Australia The HEARing CRC Melbourne Victoria

Sponsors (2)

Lead Sponsor Collaborator
Cochlear Avania

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change (within subject) in speech reception threshold in noise with fixed noise level at 65 dB SPL Speech perception in noise will be measured using the Australian Speech Test in Noise (AuSTIN), which is a test that uses Bamford-Kowal-Bench (BKB)-like target sentences presented in adaptive noise. The AuSTIN corpus comprises 80 lists of 20 sentences each, recorded in female voice. The goal of the adaptive Speech-in-Noise test is to obtain the Speech Reception Threshold in noise. During week 24-26
Primary Change (within subject) in word recognition score in quiet measured at 65 dB SPL Speech perception in quiet will be measured using the consonant-nucleus-consonant (CNC) monosyllabic words presented at 65 dB SPL from the front speaker. The goal of speech perception assessment in quiet is to obtain the percentage of correctly repeated words in a list, i.e., the word recognition score. During week 24-26
Primary Change (within subject) in aided thresholds in sound field measured at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz Aided thresholds in sound field will be measured using warble tones presented from a front speaker positioned at 1 m from the subject following the modified Hughson-Westlake procedure. Frequencies to be tested are 250, 500, 750, 1000, 1500, 2000, 3000, 4000, 6000 and 8000 Hz. During week 24-26
Primary Change (within subject) in the subjective rating of different aspects of sound when listening to sound clips After listening to different sound clips with Osia 3 and the Osia 2 sound processors, the subjects will rate specific aspects of the sound, e.g., loudness or sound quality, on a Likert scale from 1 to 5 in steps of 1. A rating of 1 is least positive while a rating of 5 is most positive. They will also be asked to explain their sound quality experience in their own words per sound clip. During week 24-26
Primary Percentage of participants who preferred Osia 3 over Osia 2 sound processor Participants will be asked which device they prefer after having listened with both devices (Osia 2 and Osia 3) to different sound clips. During week 24-26
See also
  Status Clinical Trial Phase
Completed NCT05086809 - Investigation of an Updated Bone-anchored Sound Processor N/A
Recruiting NCT05615649 - Expanded Indications in the Pediatric BONEBRIDGE Population N/A
Completed NCT04147611 - Remote Microphone (RM) - A Comparative Study N/A
Recruiting NCT06058767 - Preschool Hearing Screening N/A
Completed NCT03333577 - Evaluation of the Baha SoundArc in Pediatric Patients N/A
Completed NCT03766152 - Audiological Benefit and Improved Quality of Life With Two Bone Conduction Systems: ADHEAR vs. Bonebridge in Experienced Users N/A
Active, not recruiting NCT03742089 - Evaluation of the BHX Implant in Children With a BAHS
Completed NCT01822119 - Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System) N/A
Recruiting NCT04803279 - Investigating Hearing With Ponto 3 SuperPower, a Bone Anchored Hearing Aid - Investigating Hear
Not yet recruiting NCT04427631 - Exploring Interventions for Glue Ear During Covid-19 N/A
Completed NCT02022085 - Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System) N/A
Completed NCT01738490 - Long-term Stability and Survival Rates of a Novel Oticon Medical Bone Conduction Device Implant N/A
Recruiting NCT05055115 - Ph.D.-Project: Eustachian Tube Dysfunction: Causes, Diagnosis, Treatment, and Prognosis N/A
Completed NCT03129191 - Audiological Benefit With Non-implantable Bone Conduction Hearing Systems N/A
Recruiting NCT04899037 - Pilot Study to Evaluate the Long-term Chronic Care of Patients Who Could or do Utilize an Osseointegrated Device (OID)
Completed NCT01858246 - A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge N/A
Active, not recruiting NCT05166265 - Clinical Investigation Study of Safety and Performance of the Sentio System. N/A
Completed NCT04761926 - Investigating Hearing With the Ponto 4, a Bone Anchored Hearing Aid N/A
Completed NCT01796236 - Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique N/A
Completed NCT06256081 - Testing a New App for Children With Glue Ear N/A